On April 18, 2026, the Breakthrough Prize Foundation announced the winners of the 2026 Life Sciences prizes — and the three awards tell a single, connected story about where gene therapy stands today. Across inherited blindness, sickle cell disease, and ALS, the science being honored is not theoretical. It is already changing lives. And in one case, it has already produced a cure.
PRIZE ONE — RESTORING VISION THROUGH GENE REPLACEMENT
Jean Bennett, Katherine A. High, and Albert Maguire have been recognised for the development of Luxturna — the first gene replacement therapy to receive FDA approval for an inherited genetic disease. The condition targeted was Leber congenital amaurosis, caused by mutations in the RPE65 gene, which renders the retina progressively unable to respond to light. Patients born with the condition experience severe visual impairment from birth, with continued deterioration leading to total blindness in early adulthood. Bennett and Maguire — a husband-and-wife team of molecular biologist and ophthalmic surgeon — spent over a decade developing a delivery system capable of introducing a functional copy of the RPE65 gene directly into the retina. Early preclinical studies, including work with dogs carrying an equivalent inherited retinal disorder, demonstrated clear restoration of visual function. Human clinical trials commenced in 2005, with the first patients treated in 2007 recording measurable and sustained improvements in vision. Luxturna received FDA approval in 2017. Today, most eligible patients in the United States have received the therapy, with documented maintenance of improved vision more than a decade after a single administration. Beyond its direct clinical impact, the programme established the regulatory and manufacturing frameworks that have since supported over a dozen additional gene therapy approvals and more than 100 retinal gene therapy trials currently underway worldwide.
PRIZE TWO — GENE EDITING AS A CURATIVE INTERVENTION FOR BLOOD DISORDERS
Stuart H. Orkin and Swee Lay Thein have been recognised for research that provided the biological foundation for the first approved CRISPR-based therapy in medical history. Sickle cell disease and beta-thalassemia are inherited haemoglobin disorders affecting tens of millions of people globally, with the highest disease burden concentrated in sub-Saharan Africa, the Middle East, and South Asia. Both conditions arise from genetic defects in the production of adult haemoglobin — resulting in chronic anaemia, organ damage, and in severe cases, significantly reduced life expectancy. Thein identified a key genetic locus associated with the natural persistence of foetal haemoglobin in adult life — a phenomenon observed to substantially reduce disease severity in affected individuals. Orkin subsequently identified BCL11A as the gene responsible for suppressing foetal haemoglobin production after birth, and demonstrated that targeted inhibition of its regulatory control region could reactivate foetal haemoglobin at therapeutically meaningful levels. This mechanistic insight was translated into a CRISPR-based gene editing therapy developed through collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics. The resulting treatment — the first CRISPR therapy approved for clinical use — does not manage the symptoms of sickle cell disease and beta-thalassemia. It addresses their genetic cause directly, offering patients a one-time intervention with the potential for permanent disease resolution.
PRIZE THREE — IDENTIFYING THE GENETIC ARCHITECTURE OF ALS AND FRONTOTEMPORAL DEMENTIA
Rosa Rademakers and Bryan Traynor have been recognised for a discovery that fundamentally reorganised scientific understanding of two of the most severe neurodegenerative diseases in medicine. In 2011, working independently — Rademakers at the Mayo Clinic and Traynor at the National Institutes of Health — both researchers identified an abnormal hexanucleotide repeat expansion in the C9orf72 gene. The mutation was found to account for a substantial proportion of familial ALS and frontotemporal dementia cases across European populations, as well as a significant share of cases previously classified as sporadic. The implications of the discovery were immediate and far-reaching. It established, for the first time, that ALS and frontotemporal dementia share a common genetic origin — unifying what had been treated as distinct clinical entities within a single disease spectrum. It provided a definitive molecular target for therapeutic development. And it enabled genetic testing for at-risk families, offering a diagnostic clarity that had not previously existed. Multiple targeted therapeutic programmes — including antisense oligonucleotide and gene-silencing approaches — are currently in active clinical development on the basis of this discovery. Neither ALS nor frontotemporal dementia has yet been cured. But the C9orf72 finding has established the biological foundation from which curative interventions may ultimately be built.
THE SIGNIFICANCE OF THE 2026 AWARDS
The three 2026 Breakthrough Prizes in Life Sciences are not independent recognitions. They represent a coherent arc of scientific progress — from the first demonstration that a functional gene could be delivered to a diseased tissue and restore its function, to the first therapeutic reactivation of a dormant gene to eliminate a blood disorder, to the identification of the genetic mutation underlying two of the most intractable neurological conditions in modern medicine. Each prize marks a point at which gene therapy moved from scientific hypothesis to clinical reality. Taken together, they document the maturation of an entire field — one that is no longer defined by what it promises, but by what it has already delivered.
